Objective To investigate clinical significance of ticagrelor in treatment of patients with high inflammatory response after emergency percutaneous coronary intervention (PCI).

Methods A total of 100 patients diagnosed with acute inferior myocardial infarction and high levels of hypersensitive C-reactive protein (hs-CRP) who underwent emergency PCI were selected as study objects.These patients were randomly divided into two groups according to different medication methods.The control group was given antiplatelet therapy by clopidogrel for 12 months after PCI, while the observation group was given antiplatelet therapy byticagrelor for 12 months after PCI.The levels of serum inflammatory factors of two groups were compared before operation and 1 month after operation.Twelve months after PCI, coronary angiography and coronary ultrasound were reviewed to observe the proportion of patients with in-stent restenosis and new coronary artery disease.

Results The levels of hs-CRP, interleukin-6(IL-6), tumor necrosis factor-α(TNF-α), and advanced glycation end products (AGEs) after operation in the two group were lower than those before treatment, and were significantly lower in the observation group than those in the control group (P < 0.05).Compared with the control group, the proportions of stent restenosis, new right coronary artery disease and other new coronary artery disease in the observation group were lower, and the differences were statistically significant (P < 0.05).After 12 months of treatment, coronary artery lesions was significantly correlated with the levels of hs-CRP, IL-6, TNF-α and AGEs 1 month after PCI (P < 0.05).There was no significant difference in occurrence of adverse reactions between two groups during treatment (P>0.05).

Conclusion Ticagrelor can effectively reduce the levels of inflammatory factors in patients with high inflammation response after emergency PCI, and reduce occurrence of long-term coronary events compared with clopidogrel.